Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor

Autor: Siravegna, G. ^†, Sartore-Bianchi, A. ^†, Mussolin, B. ^†, Cassingena, A., Amatu, A., Novara, L., Buscarino, M., Corti, G., Crisafulli, G., Bartolini, A., Tosi, F., Erlander, M., Di Nicolantonio, F., Siena, S. ^#, Bardelli, A. ^{*, #}

Publikováno v: In Annals of Oncology June 2017 28(6):1302-1308

A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.

Autor: Wang D; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Veo B; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Pierce A; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Fosmire S; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Madhavan K; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Balakrishnan I; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Donson A; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Alimova I; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Sullivan KD; Linda Crnic Institute for Down Syndrome, Department of Pediatrics, Section of Developmental Biology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Joshi M; Functional Genomics Facility, University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Erlander M; Cardiff Oncology Inc., San Diego, California, USA., Ridinger M; Cardiff Oncology Inc., San Diego, California, USA., Foreman NK; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Neurosurgery, University of Colorado Denver, Aurora, Colorado, USA., Venkataraman S; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA., Vibhakar R; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Neurosurgery, University of Colorado Denver, Aurora, Colorado, USA.

Publikováno v: Neuro-oncology [Neuro Oncol] 2022 Mar 12; Vol. 24 (3), pp. 414-426.

Potential Therapeutic Targets in Triple‐Negative Breast Cancer Based on Gene Regulatory Network Analysis: A Comprehensive Systems Biology Approach.

Autor: Ahmadi, Maryam¹ (AUTHOR), Barkhoda, Neda¹ (AUTHOR), Alizamir, Aida² (AUTHOR), Taherkhani, Amir³ (AUTHOR) amir.007.taherkhani@gmail.com, Tyagi, Abhishek (AUTHOR) atyagi@wakehealth.edu

Publikováno v: International Journal of Breast Cancer. 10/22/2024, Vol. 2024, p1-16. 16p.

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Autor: Zeidan AM; Yale University and Yale Cancer Center, New Haven, Connecticut. amer.zeidan@yale.edu., Ridinger M; Cardiff Oncology, San Diego, California., Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, Kansas., Becker PS; Division of Hematology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Schiller GJ; Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Patel PA; University Hospital Bone Marrow Transplant Clinic, Dallas, Texas., Spira AI; Virginia Cancer Specialists, Fairfax, Virginia., Tsai ML; Minnesota Oncology, Minneapolis, Minnesota., Samuëlsz E; Cardiff Oncology, San Diego, California., Silberman SL; SLS Oncology LLC, Durham, North Carolina., Erlander M; Cardiff Oncology, San Diego, California., Wang ES; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Dec 01; Vol. 26 (23), pp. 6132-6140. Date of Electronic Publication: 2020 Sep 30.

1066O - Polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib

Autor: Zeidan, A., Becker, P., Patel, P., Schiller, G., Tsai, M.L., Lin, T., Wang, E., Erlander, M., Cortes, J.

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v435-v435